ASIAN AMERICAN MEDICAL GROUP LIMITED(AJJ)

A copy of the company's minutes documenting key decisions about the company's administration (where the administration is not under S.436E or S.439A) are lodged with ASIC.

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

The company notifies ASIC of the appointment or cessation of a director or company secretary.

The company notifies ASIC of the appointment or cessation of a director or company secretary.

ASIC is advised that the administrator has completed their duties and the administration process has concluded.

ASIC is notified of the appointment or replacement of an administrator of the Deed of Company Arrangement.

A copy of the Deed of Company Arrangement is lodged with ASIC.

A copy of the company's minutes documenting key decisions about the company's administration are lodged with ASIC.

The administrator provides creditors with a detailed analysis of the company's financial position and options for its future.

The administrator provides creditors and stakeholders with a detailed update on the company's financial situation, assets, and activities.

A copy of the company's minutes documenting key decisions about the company's administration are lodged with ASIC.

Richard Albarran, Roberto Crispino and Aaron Dominish of Hall Chadwick appointed Administrators

delisted by ASX under Listing Rule 17.12

we understand ASX removed the company from listing because its securities have been suspended from quotation for a continuous period of two years

The company lodges its August 2023 Quarterly Update.

The company lodges its Appendix 4C Quarterly Cash Flow Report.

The company lodges its May 2023 Quarterly Update.

The company lodges its Quarterly Appendix 4C Cash Flow Report.

The company lodges its Half Yearly Report and Accounts.

The company lodges its Quarterly Appendix 4C Cash Flow Report.

The company releases the results of its meeting.

The Company is expecting to receive an updated commitment from Saorsa Health No. 1 Pty Ltd to raise $3 million in capital through the placement of a total of 70,175,439 new fully paid ordinary shares in the Company at an issue price of A$0.0285 per New Share and the issue of 1,000,000 convertible notes at a face value of $1.00 each. Completion of the Placement has been delayed, but is now expected to occur in February 2023. It is expected that the funds for the Placement will be subscribed by Saorsa in February 2023 and that the issue of all New Shares under the Placement will occur at the same time in one tranche. It is anticipated that the issue of New Shares will occur shortly after receipt of subscription funds.

The company's AGM will be held on Monday, 30 January 2023 at 11.00am ACDT at 25 Peel Street, Adelaide, South Australia, Australia.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The company releases an Appendix 4G.

The company lodges its Annual Report to shareholders.

The Company will hold its 2022 Annual General Meeting on: Monday, 16 January 2023 at 11.00am ACDT at Ground Floor 25 Peel Street ADELAIDE SA 5000.

The company releases a notice of proposed issue of securities.

A$3.0 million total capital raising, comprising A$2.0m by a share placement (approximately a quarter of which is subject to shareholder approval) and a A$1.0 million convertible note issue (subject to shareholder approval) to raise funds for working capital and business growth and reduce certain debt obligations. Reinvigoration of the Company's medical services business. Company seeks reinstatement of trading on the Australian Securities Exchange.

The company lodges its Appendix 4E Preliminary Final Report.

The company lodges its Half Year Accounts.

The clinical operations of wholly-owned subsidiary, Asian American Liver Centre Pte Ltd, has been relocated to 6 Napier Road, Gleneagles Medical Centre, #05-16, Singapore 258499, with effect from 18 April 2022. This follows the statutory demand and repossession of its premises at 6A Napier Road, Gleneagles Hospital Annexe Block, #02-37, Singapore 258500 by Parkway Hospital Singapore Pte Ltd against AALC for unpaid lease rentals.

The company releases the results of its meeting.

Given the sudden passing of Dr Tan the company has been delayed in the process of recruiting an Australian resident director.

The company's AGM will be held virtually on 19 January 2022 at 11.00 am Adelaide time.

The company made a correction to the date of its AGM. The Annual General Meeting will be held be held on Wednesday the 19th January 2022 at 11.00am Adelaide time by a virtual meeting.

The Board of Directors have decided to defer the annual general meeting of the company originally scheduled for Wednesday the 8th December 2021. The annual general meeting will now be held on Wednesday the 19th January 2021 at 11.00am Adelaide time by a virtual meeting.

The company releases its Corporate Governance Council Principles and Recommendations.

The securities of Asian American Medical Group Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AJJ, pending the release of an announcement regarding the appointment of a sufficient number of directors to comply with section 201A(2) of the Corporations Act 2001

name changed from Asian Centre for Liver Diseases and Transplantation Limited